Elite Pharmaceuticals, Inc. specializes in the development of oral controlled release products, such as delayed, sustained, targeted and pulsatile release tablets, pellets, capsules, granules and powders.  The Company’s primary focus is in the therapeutic areas of pain management, allergy, cardiovascular and infection.

Recent Press Releases:

5/21/2013	ELITE PHARMACEUTICALS ANNOUNCES CHANGE IN EXECUTIVE LEADERSHIP
4/23/2013	ELITE PHARMACEUTICALS AWARDED SECOND U.S. PATENT FOR ABUSE RESISTANT DRUG FORMULATION
4/22/2013	ELITE PHARMACEUTICALS, INC. SECURES $10 MILLION FUNDING COMMITMENT FROM LINCOLN PARK CAPITAL FUND, LLC
4/11/2013	ELITE PHARMACEUTICALS, INC. ANNOUNCES FIRST SHIPMENT OF GENERIC PHENTERMINE CAPSULES
2/13/2013	Elite Pharmaceuticals, Inc. Announces Fiscal Year 2013 Third Quarter Investor Conference Call on Tuesday, February 19, 2013